SRR8518328
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.150
- PI3K_AKT_MTOR_SIGNALING+0.140
- APICAL_SURFACE+0.110
- CHOLESTEROL_HOMEOSTASIS+0.100
- COAGULATION+0.100
- FATTY_ACID_METABOLISM+0.100
- BILE_ACID_METABOLISM+0.080
- PEROXISOME+0.080
- TGF_BETA_SIGNALING+0.080
- ESTROGEN_RESPONSE_EARLY+0.050
Top 10 suppressed
- G2M_CHECKPOINT-0.400
- E2F_TARGETS-0.390
- INTERFERON_GAMMA_RESPONSE-0.390
- ALLOGRAFT_REJECTION-0.380
- ANGIOGENESIS-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- INFLAMMATORY_RESPONSE-0.340
- MYC_TARGETS_V2-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
- INTERFERON_ALPHA_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516058 | — | — | 0.830 |
| 2 | SRR8613720 | — | C | 0.811 |
| 3 | TCGA-E2-A1B4-01A-11R-A12P-07 | — | B | 0.808 |
| 4 | MNG27 | — | — | 0.800 |
| 5 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.792 |
| 6 | TCGA-55-8087-01A-11R-2241-07 | — | cohortA1 | 0.790 |
| 7 | SRR12475149 | — | — | 0.789 |
| 8 | ERR2278853 | — | — | 0.783 |
| 9 | C3L-00893 | — | cohortA1 | 0.781 |
| 10 | SRR6013557 | — | cohortA1 | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |